Current Surgical Management of Ovarian Cancer

被引:42
作者
Schorge, John O. [1 ]
Eisenhauer, Eric E. [2 ]
Chi, Dennis S. [3 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
关键词
Ovarian cancer; Primary debulking surgery; Interval debulking surgery; Secondary debulking surgery; PRIMARY CYTOREDUCTIVE SURGERY; RECURRENT EPITHELIAL OVARIAN; RANDOMIZED PHASE-III; STAGE-I OVARIAN; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; DEBULKING SURGERY; IMPROVES SURVIVAL; PROGRESSION-FREE;
D O I
10.1016/j.hoc.2011.10.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgical management of ovarian cancer requires excellent judgment and mastery of a wide array of procedures. Involvement of a gynecologic oncologist improves outcomes. Staging of apparent stage I disease is important. Minimally invasive techniques provide advantages. Primary debulking surgery provides the best long-term survival of any strategy in advanced ovarian cancer. Aggressive surgical paradigms have the greatest success. Further cytoreductive surgery may be appropriate. Most relapsed patients require management of bowel obstruction at some point. Palliative intervention can enhance quality of life. Surgical correction may extend survival. For end-stage patients with progressive disease, the treating gynecologic oncologist must manage expectations.
引用
收藏
页码:93 / +
页数:18
相关论文
共 78 条
  • [1] Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer
    Aletti, GD
    Dowdy, SC
    Podratz, KC
    Cliby, WA
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 283 - 287
  • [2] Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic Experience
    Aletti, Giovanni D.
    Dowdy, Sean C.
    Gostout, Bobbie S.
    Jones, Monica B.
    Stanhope, Robert C.
    Wilson, Timothy O.
    Podratz, Karl C.
    Cliby, William A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 208 (04) : 614 - 620
  • [3] [Anonymous], 2011, Obstet Gynecol, V117, P742, DOI 10.1097/AOG.0b013e31821477db
  • [4] [Anonymous], COCHRANE DATABASE SY
  • [5] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [6] Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
    Bristow, Robert E.
    Eisenhauer, Eric L.
    Santillan, Antonio
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 480 - 490
  • [7] Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
    Bristow, Robert E.
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 1070 - 1076
  • [8] Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: Operative technique and clinical outcome
    Bristow, Robert E.
    Peiretti, Michele
    Gerardi, Melissa
    Zanagnolo, Vanna
    Ueda, Stefanie
    Diaz-Montes, Teresa
    Giuntoli, Robert L., II
    Maggioni, Angelo
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 173 - 177
  • [9] Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
    Bristow, Robert E.
    Puri, Isha
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 265 - 274
  • [10] Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?
    Brown, Jubilee
    Sood, Anil K.
    Deavers, Michael T.
    Milojevic, Ljiljana
    Gershenson, David M.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 113 (01) : 86 - 90